Common Heart Medication Recalled Nationwide for Possible Cancer Link

New guidelines released in 2025 from the American Heart Association and the American College of Cardiology emphasize the link between unchecked high blood pressure and increased risks of not only heart problems and stroke, but also dementia and cognitive decline. The American Heart Association states, “If you have high blood pressure, lowering it now may help protect your brain health in the future.” However, a recall of a common heart medication has raised a separate concern regarding potential health risks.

Heart Medication Recall

On January 30, 2026, the U.S. Food and Drug Administration (FDA) announced a recall affecting an unspecified number of 100-count bottles of Bisoprolol Fumarate (2.5 milligrams) and Hydrochlorothiazide (6.25 milligrams) tablets. These tablets were distributed throughout the United States and Puerto Rico.

Reason for the Recall

The FDA initiated the recall due to “cGMP Deviations,” specifically because the tablets did not meet the acceptable impurity specification limits for N-Nitroso Bisoprolol. According to an FDA explainer, Current Good Manufacturing practise (CGMP) regulations are designed to ensure pharmaceutical quality. Failure to comply with these regulations can result in a drug being considered “adulterated” under the law.

Did You Know? Bisoprolol and hydrochlorothiazide are often prescribed together to treat high blood pressure, with bisoprolol acting as a beta-blocker and hydrochlorothiazide functioning as a diuretic.

The issue centers around FDA guidance regarding acceptable intake limits for nitrosamine impurities in drug substances. While nitrosamines are commonly found in foods like cured meats and vegetables, their presence in drugs at levels exceeding acceptable limits “may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time,” according to the FDA.

Specifics of the Recalled Medication

Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg
100-count bottle, Rx Only
Lot #: GBHL24005A
Expiration date: 09/2026
Manufactured by: UNICHEM LABORATORIS LTD., Pilerne Ind. Estate, Pilerne, Bardez, Goa 403 511, India
Manufactured for: UNICHEM PHARMACEUTICALS (USA), INC., East Brunswick, NJ 08816, NDC 29300-187-01

Expert Insight: The FDA’s classification of this recall as a Class II event suggests the potential health consequences are likely temporary or reversible, or that the probability of serious harm is remote. However, the presence of impurities always warrants careful attention and adherence to agency guidance.

The recall was initiated on January 21, 2026, and as of January 30, 2026, the FDA has classified it as a Class II event. This classification indicates that exposure to the violative product may cause temporary or medically reversible health consequences, or that the probability of serious adverse health consequences is remote.

What Should Patients Do?

The FDA advises patients currently taking affected prescriptions not to stop their medications. Instead, they should consult with their healthcare provider to address any concerns and discuss alternative treatment options.

Frequently Asked Questions

What prompted the recall of Bisoprolol Fumarate and Hydrochlorothiazide tablets?

The recall was initiated due to “cGMP Deviations” and the tablets not meeting the acceptable impurity specification limits for N-Nitroso Bisoprolol.

What is a Class II recall?

A Class II recall, as defined by the FDA, is a situation where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

What should patients do if they are taking the recalled medication?

The FDA recommends that patients continue taking their medication but consult with their healthcare provider regarding any concerns or to discuss alternative treatment options.

Considering the interplay between managing blood pressure and safeguarding long-term cognitive health, what steps can individuals proactively take to prioritize both cardiovascular and brain wellness?